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hypertensionAbstract Introduction: End-stage liver disease and its complications are a leading cause of death
among adults. The liver plays a central role in health and homeostasis and thus the diseased liver
leads to many deleterious effects on multiple organ systems, including the pulmonary system Julie
et al. (2007) [1]. A variety of causes for pulmonary dysfunction in liver disease have been identiﬁed
and include intrinsic cardiopulmonary disorders not speciﬁcally related to liver disease as well as
unique problems associated with the presence of liver disease and/or portal hypertension Michael
et al. (2000) [2]. Liver disease and portal hypertension can be associated with pulmonary vascular
complications, including portopulmonary hypertension (POPH), and hepatopulmonary syndrome
(HPS) Mateo et al. (2012) [3].
Aim: This study aimed to evaluate the pulmonary dysfunctions complicating liver cirrhosis.
Patients and methods: Fifty patients with liver cirrhosis without intrinsic cardiopulmonary dis-
ease were enrolled in this study. All were subjected to complete clinical examination, laboratory
investigations, radiological investigations including abdominal ultrasound, chest x ray and CT chest,
ECG, contrast enhanced echocardiography with colored Doppler study, gastroscopy, ventilatory
function tests, measurement of SaO2 using portable pulse oximetry and arterial blood gas analysis.
Results: The prevalence of arterial hypoxemia in cirrhotic patients was 14.6%. The presence of
hypoxemia is increased in patients with advanced liver disease and the severity of hypoxemia was pos-
itively correlated with the severity of liver disease assessed by the Child Pugh score. HPS represents
64.1% of causes of hypoxemia. Pulse oximetry is a simple non-invasive method for detection of arte-
rial hypoxemia as an initial screening test for HPS. Contrast enhanced echocardiography (CEE) is the
gold standard method for the diagnosis of HPS by detection of intrapulmonary vasodilatation (IPV)
characteristic of HPS, while CT chest assists in diagnosis by exclusion of intrinsic pulmonary disease.
Conclusion: Liver cirrhosis is associated with unique pulmonary complications. The early identi-
ﬁcation of pulmonary dysfunctions in cirrhotic patients is crucial as it affects the prognosis and guides
the future management by speeding up orthotopic liver transplantation (OLT) recommendations.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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Pulmonary abnormalities and symptoms are common in
patients with chronic liver disease. If questioned, up to 70%
of cirrhotic patients undergoing evaluation for liver transplan-
tation complain of dyspnea [4]. Mild hypoxia has been seen in
approximately one third of patients with chronic liver disease.
Development of hypoxemia in patients with chronic liver dis-
ease modiﬁes the line of management and worsens the progno-
sis of the disease [5].
There is no simple mechanism to explain the association
between liver disease and hypoxemia and that probably many
factors have a role in its pathogenesis [6]. Although none of
them have been proven as the sole reason, nevertheless ascites,
hepatopulmonary syndrome, increased closing volume, low
albumin levels, anemia, respiratory muscle weakness and
extreme hepatomegaly are still considered among the factors
implicated in the pathogenesis of hypoxemia in cirrhosis [7].
A variety of causes for pulmonary dysfunction in liver dis-
ease have been identiﬁed and include intrinsic cardiopulmo-
nary disorders not speciﬁcally related to liver disease as well
as unique problems associated with the presence of liver dis-
ease and/or portal hypertension [2].
Causes of pulmonary abnormalities in chronic liver disease [8]
Intrinsic cardiopulmonary disease Speciﬁc to liver disease
(1) Chronic obstructive
pulmonary disease
(A) Associated with speciﬁc liver
diseases. Panacinar emphysema:
alpha-1 antitrypsin deﬁciency
Fibrosing alveolitis, pulmonary
granulomas: primary biliary
cirrhosis
(2) Congestive heart
failure
(B) Fluid retention complicating
portal hypertension. Ascites –
Hepatic hydrothorax
(3) Pneumonia (C) Pulmonary Vascular
abnormalities: hepatopulmonary
syndrome – Portopulmonary
hypertension
(4) AsthmaHepatopulmonary syndrome (HPS) is a serious vascular com-
plication of liver disease that occurs in 5–32% of patients with
cirrhosis [9]. Pulmonary vascular bed abnormalities of HPS
can be of two distinct types: diffuse, microscopic precapillary
and capillary dilatations, and discrete, macroscopic arteriove-
nous communications that may resemble classic pulmonary
arteriovenous malformations [10]. The presence of HPS
increases mortality in cirrhotic patients and may inﬂuence
the frequency and severity of complications of portal hyperten-
sion [11]. The diagnostic features of HPS include evidence of
liver disease or portal hypertension, an elevated age-adjusted
alveolar-arterial oxygen gradient (AaPO2) and evidence of
intrapulmonary vasodilatation. Treatment of HPS consists of
supplemental oxygen and consideration of orthotopic liver
transplantation if signiﬁcant hypoxemia is present [12].
PPHT is deﬁned as precapillary pulmonary hypertension
accompanied by hepatic disease or portal hypertension in theabsence of other known causes of pulmonary arterial hyper-
tension [13]. The reported prevalence of PPHT in cirrhotic
patients ranges from 0.25% to 16%, which is inﬂuenced by
patient characteristics, diagnostic criteria and the diversity of
study designs [14].
Although the pathogenesis of PPHT is unknown, causative
factors that may lead to the development of structural pulmon-
ary changes include: (1) shear stress in the vascular walls due to
increased blood ﬂow in a hyperdynamic state of circulation; (2)
a volume phenomenon as a consequence of the increased pul-
monary vascular volume; and (3) vasoconstrictive substances
such as endothelins (ETs) [15]. Although observations suggest
that portopulmonary hypertension is a complication affecting
mainly patients with advanced liver disease, no clear relation
between the severity of hepatic dysfunction or raised portal
venous pressure and the severity of pulmonary hypertension
has been conclusively shown [16].
The most common presenting symptom in patients with
pulmonary hypertension, irrespective of its cause, is progres-
sive dyspnea on exertion. Other symptoms such as fatigue,
palpitations, syncope or chest pain are less frequent. Physical
ﬁndings indicating pulmonary hypertension are generally subtle
and may be completely absent. The most common ﬁndings are
an accentuated pulmonary component of the second heart
sound and a systolic murmur, indicating tricuspid regurgitation
[17].
Subjects and methods
This study was conducted on 50 patients with liver cirrhosis
after written consent. It was carried out during the period
between December 2012 and December 2013 at the Al Madina
National Hospital and Al Dar Hospital (Al Madinah Al
Munawara). The diagnosis of liver cirrhosis was made on the
basis of clinical examination, laboratory investigations and
abdominal ultrasound examination. The severity of liver cir-
rhosis was assessed according to the Child-Pugh classiﬁcation.
Patients were divided into two groups according to the pres-
ence of arterial hypoxemia:
Group I: included 9 cirrhotic patients with arterial hypox-
emia: 2 patients were Grade A, 2 patients were Grade B and
5 patients were Grade C according to the Child Pugh score.
Patients were subdivided according to the severity of arterial
hypoxemia into two subgroups:
Subgroup Ia: included 6 patients with mild to moderate
arterial hypoxemia.
Subgroup Ib: included 3 patients with severe arterial
hypoxemia.
Group II: included 41 cirrhotic patients with normal arterial
oxygen pressure. 12 patients were Grade A, 21 patients were
Grade B and 8 patients were Grade C according to the Child
Pugh score.
Arterial hypoxemia was diagnosed when partial pressure of
arterial oxygen (PaO2) is less than 80 mmHg at the arterial
blood gas analysis. Arterial hypoxemia was considered:
 Mild to moderate hypoxemia: when PaO2 is between 60
and 79 mmHg.
 Severe hypoxemia: when PaO2 is less than 60 mmHg.
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1- Complete clinical examination including history taking
(including smoking history) and clinical examination
with special emphasis on abdominal, heart and chest
examinations.
2- Laboratory investigations including: complete blood
count, ESR, fasting blood sugar, liver functions tests
(Bilirubin total and direct, prothrombin time, serum
albumin, AST, ALT, alkaline phosphatase, gamma glut-
amyl transferase, prothrombin time), kidney function
tests, HCV Ab, HBsAg, ANA, ASMA, Anti LKM1
Ab, serum alfa fetoprotein.
3- Electrocardiography (ECG).
4- Radiological investigations including:
 Plain chest x ray postero-anterior and lateral views.
 Abdominal ultrasonography (using convex probe 5 MHz of
a GE logic 9 machine). We assess liver morphology, portal
vein diameter, splenomegaly and ascites.
 CT chest with contrast (using GE MDCT 64 slice). We
stress upon ﬁndings suggestive of interstitial lung disease
(ground glassing, reticulation, nodulation, honey combing
and ﬁbrosis), presence/absence of pleural effusion and its
amount, assessment of peripheral pulmonary vascular dila-
tation at the base of the right lung (we deﬁne the peripheral
vessels as the vessels located 2 cm from the pleural surface),
we measure the diameter of the peripheral pulmonary arte-
rioles and calculate the arteriole/bronchiole (A/B) ratio
which is the ratio between the diameter of the peripheral
arteriole and its adjoining bronchiole, and other CT ﬁnd-
ings were also documented.
5- Esophagogastroduodenoscopy to detect signs of portal
hypertension as esophageal varices.
6- Measurement of O2 saturation (SaO2) with portable
pulse oximetry. In all patients, the measurements were
performed at room O2 partial pressure in the supine
position.
7- Ventilatory function tests (spirometry) during exacerba-
tion and stable condition before and after bronchodila-
tation using a Spiro analyzer ST-95, serial number
67011870, Fukuda Sangyo 2003 were performed. The
best of three consecutive spirometry recordings were
used. Measurements included assessments of PEFR%
(peak expiratory ﬂow rate %), FEV1 (forced expiratory
volume in ﬁrst second), and FEF 25–75% (forced expi-
ratory ﬂow, 25–75%).
8- Arterial blood gas analysis on room air: blood samples
were obtained by puncture of radial artery and analyzed
using blood gas analyzer.
9- Contrast Echo heart and colored Doppler: Using avail-
able equipment (GE VIVID 7) with 2.5 MHz transducer
using standard views by using agitated saline which cre-
ates a stream of microbubbles after intravenous injec-
tion. Under normal circumstances, these microbubbles,
60–90 lm in diameter opacify only the right heart cham-
bers because they are ﬁltered in the pulmonary capillary
bed and do not appear in the left side of the heart. In
case of the presence of intrapulmonary vascular dilata-
tion, the microbubbles appear in the left-heart chambers
4–6 heart beats after their initial visualization in the
right side of the heart.Heptopulmonary syndrome was diagnosed after detection
of intrapulmonary vascular dilatation (IPVD) by contrast
enhanced echocardiography in cirrhotic patients with arterial
hypoxemia.
Portopulmonary hypertension was diagnosed when the
mean pulmonary artery pressure measured by Doppler echo-
cardiography is >25 mmHg at rest and >30 mmHg during
exercise in the presence of a pulmonary arterial occlusion pres-
sure; or a left-ventricular end diastolic pressure of less than
15 mmHg in patients with coexisting portal hypertension [18].
Portal hypertension was diagnosed clinically and conﬁrmed
by detection of esophageal varices.
Exclusion criteria
1- Patients with coexisting primary pulmonary pathology.
2- Coexisting intrinsic heart disease.
3- Active smokers were excluded.Statistical analysis of data
The collected data were organized, tabulated and statistically
analyzed using the SPSS software computer package. For
qualitative data, frequency and percent distribution were cal-
culated and for comparison between groups, the chi square test
was used. For quantitative data, mean and standard deviation
were calculated and for comparison between two groups, stu-
dent’s t test was used. P 6 0.05 was considered signiﬁcant for
interpretation of results.
Results
This study was carried on 50 patients with liver cirrhosis. 28
patients (56%) were males and 22 patients (44%) were females,
their mean age was 53.52 ± 4.12 years. Patients were classiﬁed
into two groups according to PaO2. Data of both groups
were collected. Statistical analysis of the data showed the
following:
There was no statistically signiﬁcant difference between
both groups as regards age, gender or the etiology of liver
cirrhosis.The baseline clinical characteristics of group I patients are as
follows
Dyspnea was evident in 12 patients (100%), central cyanosis in
5 patients (55.5%), spider naevi in 6 patients (66.6%), ascites
in 7 patients (77.7%), cough in 2 patients (22.2%), clubbing
of ﬁngers in 6 patients (66.6%), pleural effusion in 3 patients
(33.3%), and orthodeoxia (dyspnea in upright position) in 5
patients (55.5%).
The baseline clinical characteristics of group II patients are as
follows
Ascites was evident in 29 patients (70.7%), spider naevi in 12
patients (29.2%), pleural effusion in 2 patients (7.1%), dysp-
nea in 5 patients (12.1%), and clubbing of ﬁngers in 2 patients
(4.8%).
Table 2 Statistical study of the severity of cirrhosis among
group I patients.
Parameter
Variable Mean S.D P
Child Pugh score Subgroup Ia 8.71 0.62 0.001(S)
Subgroup Ib 10.01 0.32
Table 3 Statistical study of laboratory parameters of group I
in comparison to group II.
Parameter
Variable Mean S.D P
ALT (U/L) Group I 68.9 53.4 >0.01 (NS)
Group II 88.4 74.8
AST (U/L) Group I 48.8 50.2 >0.01 (NS)
Group II 58.4 63.7
Albumin (gm/dl) Group I 2.3 0.4 <0.01 (S)
Group II 2.9 0.6
PT (seconds) Group I 15.03 0.8 <0.01 (S)
Group II 17.10 0.63
Hb (gm/dl) Group I 11.6 2.1 >0.01(NS)
Group II 11.1 2.2
1082 A.M. Helmy, M.F. AwadallahHepatopulmonary syndrome was diagnosed in 6 hypoxemic
patients. Four patients were child C, one patient was child B
and one patient was child A. 4 HPS patients presented with
severe hypoxemia, 2 patients presented with mild to moderate
hypoxemia. Dyspnea was the main symptom while orthode-
oxia was detected in 5 patients (83.3%).
Pleural effusion (moderate to severe) was the cause of hyp-
oxemia in 3 patients. CT chest showed free accumulation of
hypodense ﬂuid within the pleural sac with subsequent com-
pression consolidation collapse of the underlying lung
parenchyma.
PPHT was diagnosed in 3 patients. 2 patients were child B,
one patient was child C. Exertional dyspnea was the main pre-
senting symptom. All patients had normal arterial oxygen
pressure.
 There was a statistically signiﬁcant increase in the severity
of cirrhosis as assessed by the Child-Pugh score of patients
with arterial hypoxemia in comparison to non-hypoxemic
patients as shown in Table 1.
 There was a statistically signiﬁcant increase in the Child-
Pugh score in patients with severe hypoxemia in compari-
son to patients with mild to moderate hypoxemia as shown
in Table 2.
 There was a statistically signiﬁcant decrease in serum albu-
min and increase in prothrombin time of group I patients in
comparison to group II, while serum transaminases and
hemoglobin levels showed no statistically signiﬁcant differ-
ence between both groups as shown in Table 3.
 There was a statistically signiﬁcant decrease in PaO2 in
both supine and erect positions and O2 saturation in
group I patients in comparison to group II, while FVC,
FEV1, FEV1/FVC and FEF25–75 showed no statistically
signiﬁcant difference between both groups as shown in
Table 4.
 There was a statistically signiﬁcant decrease in O2 satura-
tion as well as PaO2 in both supine and erect positions in
patients with hepatopulmonary syndrome in comparison
to HPS negative hypoxemic patients. P (A-a) O2 showed
statistically signiﬁcant increase in hypoxemic patients with
HPS in comparison to HPS negative hypoxemic patients
as shown in Table 5.
 There was a statistically signiﬁcant increase in the diameter
of peripheral pulmonary arterioles as well as the arteriole/
bronchiole ratio in hypoxemic patients with HPS in com-
parison to HPS negative hypoxemic patients as shown in
Table 6.
 The sensitivity chest CT in the detection of intrapulmonary
vasodilatation (IPV) against contrast enhanced echocardi-
ography (CEE) is 80%, while the speciﬁcity is 100% as
shown in Table 7.Table 1 Statistical study of the severity of cirrhosis of group I in c
Parameter
Variable Mean S.D
Child Pugh score Group I 8.23 0.6
Group II 6.38 1.2Discussion
Liver cirrhosis is often accompanied by arterial hypoxemia in
the absence of cardiopulmonary disease [19]. In addition,
abnormalities in pulmonary function and impaired gas
exchange may occur in as many as 45–50% of patients [20].
Although putative mechanisms of hypoxemia include an intra-
or extrapulmonary shunt, ventilation–perfusion inequality,
and alveolar capillary diffusion limitation, there is a lack of
agreement on which factors are the most important [21]. Hep-
atopulmonary syndrome (HPS) is a serious vascular complica-
tion of liver cirrhosis disease that occurs in 5–32% of patients
with cirrhosis [22]. POPH is best deﬁned as a condition charac-
terized by increased mean pulmonary arterial pressure (mPAP)
and pulmonary vascular resistance (PVR), resulting in pul-
monary arterial hypertension (PAH) in association with portal
hypertension, whether or not portal hypertension is related to
underlying chronic liver disease [23]. Fluid in the chest (pleuri-
sity) may be found in at least 10 percent of patients with cir-
rhosis, being more common on the right side inﬂuencing
when in large quantities the VA/Q ratio [24].
The present study found an 18% prevalence of arterial
hypoxemia in patients with liver cirrhosis. This prevalence isomparison to group II.
Minimum Maximum P
21 6.0 12.0 0.001(S)
30 5.0 10.0
Table 5 Statistical study of PaO2, O2 saturation and P (A-a)
O2 among group I patients.
Parameter
Variable Mean S.D P
Pao2 mmHg HPS 57.23 6.21 <0.01 (S)
Non HPS 68.4 8.61
O2 Saturation % HPS 88.3 7.8 <0.01 (S)
Non HPS 93.2 9.8
P (A-a)O2 mmHg HPS 23.1 2.31 <0.01 (S)
Non HPS 15.5 3.9
Table 7 Sensitivity of chest CT against contrast enhanced
echocardiography in detection of intrapulmonary vasodilata-
tion: sensitivity = (true positive)/(true positive) + (false nega-
tive); sensitivity = 8/8 + 2 = 8/10 = 80%; speciﬁcity=(true
negative)/(true negative) + (false positive); speciﬁcity = (15/
15 + 0 = 100%).
Chest CT CEE Total
Absence of IPVD Presence of IPVD
Absence of IPVD 15 (true negative) 2 (false negative) 17
Presence of IPVD 0 (false positive) 8 (true positive) 08
Total Number 15 10 25
Table 4 Statistical study of arterial blood gases, O2 satura-
tion and spirometry results of group I in comparison to group
II.
Parameter
Variable Mean S.D P
PaO2 supine (mmHg) Group I 93.5 6.9 <0.01 (S)
Group II 75.4 4.6
PaO2 erect (mmHg) Group I 95.4 8.1 <0.01 (S)
Group II 74.9 10.8
Arterial PH Group I 7.44 0.01 >0.01 (NS)
Group II 7.43 0.01
Arterial HCO3 mmol/l Group I 22.5 0.8 >0.01 (NS)
Group II 22.1 0.2
O2 saturation (%) Group I 89.1 5.3 <0.01 (S)
Group II 97.2 7.4
FVC (%) Group I 106 18.9 >0.01 (NS)
Group II 104.0 15.9
FEV1 (%) Group I 99.9 24.2 >0.01 (NS)
Group II 94.7 21.1
FEV1/FVC (%) Group I 78 9.8 >0.01 (NS)
Group II 73.6 10.1
FEF25-75 (%) Group I 72.5 18.5 >0.01 (NS)
Group II 68.3 27.5
Study of pulmonary dysfunctions in liver cirrhosis 1083different from those reported by Hakan et al., [25] Rao et al.
[5] and Florence et al. [26] who showed a prevalence of
43.8%, 13.9% and 14% respectively. This wide variability in
the prevalence may be explained by the difference in number
of patients enrolled in each study as well as the difference in
the clinical proﬁles of the population studied (See Figs. 1–4).
The present study showed a positive correlation between
the presence of arterial hypoxemia and the severity of liver
disease assessed by the Child-Pugh score and showed that
the severity of hypoxemia is positively correlated with the
severity of liver disease. These ﬁndings agree with those done
by Florence et al. [26] who showed that, cirrhotic patients
with hypoxemia have a higher Child Pugh score than non-
hypoxemic patients and the severity of hypoxemia is positivelyTable 6 Statistical study of chest CT ﬁndings among group I patie
Parameter
HPS patients
Variable Mean
Arteriole/Bronchiole (A/B) ratio 1.8
Diameter of peripheral pulmonary arterioles 6.8correlated with the Child Pugh score and he stated that, the
role of decompensated cirrhosis in the development of
hypoxemia explains the improvement in cirrhosis-associated
hypoxemia following liver transplantation.
The present study showed a statistically signiﬁcant decrease
in serum albumin and increase in prothrombin time in hypox-
emic patients in comparison to non hypoxemic patients. These
results agree with Melot et al. [27] who showed a decreased
serum albumin in hypoxemic patients. Low serum albumin
may contribute to hypoxemia through causing subtle intersti-
tial edema which leads to impaired diffusion of alveolar O2.
Also hypoalbuminemia predisposes to ascites and hydrothorax
leads to hypoxemia. Hakan G et al. [25] showed no statistically
signiﬁcant decrease in serum albumin in hypoxemic patients
which do not agree with this study.
The present study showed no statistically signiﬁcant differ-
ence in serum transaminases (AST, ALT) and hemoglobin lev-
els in both groups. These results do not agree with Hakan et al.
[25] who showed a statistically signiﬁcant decrease in serum
AST in cirrhotic patients with hypoxemic.
The present study showed a statistically signiﬁcant decrease
in O2 saturation and PaO2 in both supine and erect positions
in patients with hypoxemia, but other parameters of ventila-
tory functions showed no statistically signiﬁcant difference
between both groups. These results agree with Konstantinos
et al. [28], and Hakan et al. [25] who showed similar results.
These results could be explained by the fact that we exclude
patients with intrinsic pulmonary disease as well as those with
active smoking from the study.
The present study showed that the severity of hypoxemia
assessed by PaO2 and SaO2 is positively correlated with the
presence of intrapulmonary shunt in HPS. These results agree
with the study done by Suceveanu et al. [29] who showed a
positive correlation between decreased SaO2 detected by pulse
oximetry and the presence intrapulmonary vasodilatation
characteristic of HPS.
The present study showed a 12% prevalence of HPS in cir-
rhotic patients. This result is different from that done by Karints.
Non HPS patients P
SD Mean SD
0.2 1.1 0.2 <0.001
1.5 3.7 0.5 <0.001
ALT                               AST                                           
0
10
20
30
40
50
60
70
80
90
68.9
48.8
88.4
58.4
Group I
Group II
Figure 1 Comparison between group I and Group II as regards
ALT and AST.
 PaO2                               P (A-a)O2 
0
10
20
30
40
50
60
70
57.23
23.1
68.4
15.5
HPS
NON HPS
Figure 2 Comparison between patients with HPS and Non HPS
as regards PaO2 and P (A-a) O2.
Figure 3 Contrast-enhanced echocardiography showing the
appearance of microbubbles in the left atrium 6 cycles after they
ﬁrst appeared in the right.
Figure 4 CT chest in patient with HPS, showed that peripherally
dilated vessels appear as linear and nodular opacities.
1084 A.M. Helmy, M.F. Awadallahet al. [31] and Thevenot et al. [32] who showed a prevalence of
24% and 20% respectively. But this result agrees with Zhang
and Fallon [30] who stated that, the prevalence of HPS in cir-
rhotic patients is 5–32%.
The present study showed a statistically signiﬁcant increase
in the diameter of peripheral pulmonary arterioles as well as
the arteriole/bronchiole ratio detected by CT chest in patientswith HPS in comparison to HPS negative hypoxemic patients.
These results do agree with Mcadams et al. [33] who showed
that CT chest in patients with HPS showed distal vascular dila-
tation which mainly concentrated in the lower lung zones.
In the present, CT chest showed no evidence of pulmonary
ﬁbrosis or other parenchymal lung disease among patients with
hypoxemia, which conﬁrms that hypoxemia, was attributed to
liver cirrhosis. The result of this study showed that the sensitiv-
ity of CT chest in diagnosis of IPV of HPS is 80%. This result
agrees with Michael et al. [25] who showed that, the sensitivity
of CT chest in diagnosis is 86.4% in contrast to the sensitivity
of CEE which is considered the gold standard method for the
diagnosis of HPS.
In the present study PPHT was diagnosed in 3 patients.
Echocardiography aids in diagnosis by detection of raised pul-
monary artery pressure and by exclusion of intrinsic heart dis-
ease causing pulmonary hypertension. CT chest helps in
diagnosis by exclusion of intrinsic pulmonary disease as inter-
stitial lung disease and obstructive airway disease. This study
showed a 6% prevalence of PPHT in liver cirrhosis which is
in the same range of most studies who showed a prevalence
between 2% and 10% as shown by Maruis et al. [34].
Conclusion: Liver cirrhosis is associated with unique pul-
monary complications. The early identiﬁcation of pulmonary
complications in cirrhotic patients is crucial as it affects the
prognosis and guides the future management by speeding up
orthotopic liver transplantation (OLT) recommendations.
Pulse oximetry is a simple non-invasive method that can be
used as an initial screening modality for early detection of hyp-
oxemia in cirrhotic patients. CEE with color Doppler is a sim-
ple non-invasive method with high sensitivity in diagnosis of
HPS as well as PPHT. CT chest has an important role in diag-
nosis by detection of IPV characteristic of HPS as well as by
exclusion of intrinsic pulmonary pathology.
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